Vistagen CFO receives grant of 75,000 stock options
Vistagen Therapeutics, Inc. reported that Chief Financial Officer Nick B. Tressler received a grant of 75,000 Incentive Stock Options to purchase common stock at an exercise price of $0.5358 per share, expiring on April 7, 2036.
Rhea-AI Filing Summary
Vistagen Therapeutics, Inc. reported that Chief Financial Officer Nick B. Tressler received a grant of 75,000 Incentive Stock Options to purchase common stock at an exercise price of $0.5358 per share, expiring on April 7, 2036.
According to the grant terms, 25% of these options will vest on the six-month anniversary of April 7, 2026, with additional 25% installments vesting every six months until the options are fully vested on the two-year anniversary of the grant date. This is a compensation award, not an open-market purchase or sale.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 75,000 shares
Grant/Award
1 txn
Insider
Tressler Nick B.
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Incentive Stock Option (right to buy) | 75,000 | $0.00 | $0.00 |
Holdings After Transaction:
Incentive Stock Option (right to buy) — 75,000 contracts (Direct)
Footnotes (1)
- F1. Represents stock options (the "Options") granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. 25% of the Options will vest on the six-month anniversary of April 7, 2026 (the "Grant Date"), and will vest in 25% installments every six months thereafter until the Options become fully vested on the two (2) year anniversary of the Grant Date.
Key Figures
Options granted: 75,000 options
Exercise price: $0.5358 per share
Expiration date: April 7, 2036
+2 more
5 metrics
Options granted
75,000 options
Incentive Stock Option grant to CFO on April 7, 2026
Exercise price
$0.5358 per share
Strike price for Incentive Stock Options
Expiration date
April 7, 2036
Option term under equity incentive plan
Post-grant derivative holdings
75,000 options
Total options held by CFO following this transaction
Initial vesting tranche
25% of options
Vests on six-month anniversary of April 7, 2026
Key Terms
Incentive Stock Option, Amended and Restated 2019 Omnibus Equity Incentive Plan, vesting, Grant Date
4 terms
Incentive Stock Option financial
"Represents stock options (the "Options") granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan"
An incentive stock option is a type of employee benefit that gives a worker the right to buy company shares at a fixed price, with special tax advantages if the employee holds the shares for a required period. Think of it as a coupon to buy future shares at today’s price that can result in lower tax on the gain. Investors care because ISOs can dilute share count, align staff incentives with the stock price, and affect company compensation costs and the timing of potential share sales.
Amended and Restated 2019 Omnibus Equity Incentive Plan financial
"granted pursuant to the Issuer's Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended"
vesting financial
"25% of the Options will vest on the six-month anniversary of April 7, 2026"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Grant Date financial
"six-month anniversary of April 7, 2026 (the "Grant Date")"
The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.
FAQ
What did Vistagen (VTGN) disclose about CFO Nick Tressler’s Form 4 transaction?
Vistagen disclosed that CFO Nick B. Tressler received a grant of 75,000 Incentive Stock Options. These options give him the right to buy Vistagen common stock at a fixed exercise price of $0.5358 per share as part of his equity compensation.
How many Vistagen (VTGN) stock options were granted to the CFO and at what price?
The CFO was granted 75,000 Incentive Stock Options covering an equal number of common shares. Each option has an exercise price of $0.5358 per share, meaning he can purchase shares at that price once the options vest and before they expire.
What is the vesting schedule of the 75,000 Vistagen (VTGN) stock options granted to the CFO?
The options vest over two years. Twenty-five percent vests on the six-month anniversary of April 7, 2026, then additional 25% portions vest every six months thereafter. The options become fully vested on the two-year anniversary of the April 7, 2026 grant date.
When do CFO Nick Tressler’s Vistagen (VTGN) stock options expire?
The 75,000 Incentive Stock Options granted to CFO Nick B. Tressler expire on April 7, 2036. He may exercise vested options any time before that expiration date, subject to the terms of Vistagen’s Amended and Restated 2019 Omnibus Equity Incentive Plan.
Is the Vistagen (VTGN) CFO’s Form 4 transaction an open-market stock purchase or sale?
No. The Form 4 reports a compensation-related grant of 75,000 Incentive Stock Options to the CFO. This is an award under Vistagen’s equity incentive plan, not an open-market purchase or sale of common shares on a stock exchange.
Under which plan were the Vistagen (VTGN) stock options granted to the CFO?
The options were granted under Vistagen’s Amended and Restated 2019 Omnibus Equity Incentive Plan, as amended. This plan governs equity awards such as stock options and sets the terms for vesting, exercise, and other key conditions of the grant.
AI-generated analysis. How Rhea-AI works. Not financial advice.
